Trial Profile
A Phase 1b/2a Dose-escalation and Safety/Efficacy Evaluation Study of Pexa-Vec (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) in Combination With Cemiplimab (REGN2810; Anti-PD-1) in Patients With Metastatic or Unresectable Renal Cell Carcinoma (RCC)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 29 Mar 2024
Price :
$35
*
At a glance
- Drugs Cemiplimab (Primary) ; Pexastimogene devacirepvec (Primary) ; Pexastimogene devacirepvec (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms REN026
- Sponsors SillaJen Biotherapeutics
- 27 Mar 2024 Status changed from active, no longer recruiting to completed, according to a SillaJen Biotherapeutics Media Release.
- 27 Mar 2024 Results presented in a SillaJen Biotherapeutics Media Release.
- 27 Mar 2024 According to a SillaJen Biotherapeutics media release, company has submitted CSR to the US FDA on 06 Feb 2024 for REN026, a phase 1b/2a dose escalation and safety/efficacy evaluation study of Pexa-Vec in combination with cemiplimab in patients with metastatic or unresectable renal cell carcinoma (RCC).